Continuing Medical Education
The Annual Meeting offers CME to eligible participants.
Purpose/Learning Outcome: Following this activity, the ANA expects learners to be better able to:
- Assimilate into their practice the latest advances in neurodiagnostics and therapeutics across the breadth of neurology.
- Apply the critical knowledge and skills necessary to analyze and perform insightful studies of diseases of the central nervous system.
- Incorporate relevant information and strategies into their plans for career development and advancement.
- Collaborate effectively with peers in academia, industry, and government to improve treatments and outcomes for patients with neurological diseases.
ACCME Accreditation & AMA Designation Statements
The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Neurological Association designates this live activity for a maximum of 23.25 AMA PRA Category 1 Credit(s)ā¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for obtaining CME
CME is immediately available and posted in different areas around the meeting to claim CME. If you don’t see the code or prefer to wait, you will receive an email with instructions to claim CME credits. Individuals who claim CME on or before Friday November 7, 2025, will be entered into a drawing for a $100 Starbucks card! CME credits can be claimed through December 31, 2025.
Click here to see a complete breakdown of how many credits are available per session.
Financial Disclosure Statements
The planners and faculty for this activity do not have any relationships to disclose unless listed here. Any relevant relationships with ACCME-defined ineligible companies are mitigated according to ACCME Standards prior to the start of the activity.
Disclosure of Commercial Support
The ANA received grants from the following ACCME-defined ineligible companies:
AbbVie
Eisai, Inc.